Study summary
Aspirin did not prevent relapse after treatment of liver metastases
What was tested
Aspirin 160 mg daily or placebo for up to 3 years after curative treatment of colorectal cancer liver metastases, not selected by tumor mutations.
What they found
- Disease-free survival did not improve.
- 3-year survival was 76% with aspirin vs 85% with placebo.
- Serious side effects were more common with aspirin (8% vs 2%).
What it means
Aspirin should not be routinely used after liver metastasis treatment without a specific tumor marker.
Lancet Gastroenterol Hepatol, via PubMed ↗
Trial record NCT03326791 ↗
← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.